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Objective: Examine the effect of ABT-335 (fenoﬁbric acid) on postprandial lipemia and susceptibility of
plasma lipoproteins to Cuþþ-mediated oxidation in patients with metabolic syndrome.
Methods and results: This is a randomized double-blind, placebo-controlled study with cross-over and
includes a 4-week wash-out period between the two treatment periods. At the end of each 8-week
treatment period, subjects were challenged with a standardized mixed meal followed by blood collec-
tion over the ensuing 6 h. Plasma lipoproteins were isolated by a combination of ultracentrifugation and
FPLC for the continuous monitoring of conjugated dienes formation as an assessment of oxidative sus-
ceptibility. Fasting plasma TG was reduced by 20% (p < 0.0002) and there was a modest reduction in
hsCRP (6.1%, p < 0.06). There was no change in either HDLc or LDLc in these subjects. Postprandial
lipemia was reduced with ABT-335 as demonstrated by a 28.5% reduction (p < 0.0005) in incremental
area under the curve for TG during the 6-h period after the meal challenge. Lag times for both fasting LDL
(þ16%) and postprandial LDL (þ28%) were increased with the ABT-335 therapy, suggestive of reduced
oxidative susceptibility. Co-incubation with autologous HDL did not reduced LDL oxidative susceptibility
in these patients.
Conclusion: ABT-335 therapy reduced fasting and postprandial triglycerides in patients with metabolic
syndrome. Autologous HDL may be dysfunctional in these patients as co-incubation with HDL failed to
reduce oxidative susceptibility of LDL. During ABT-335 therapy, LDL was less susceptible to Cuþþ-
mediated oxidative modiﬁcation, in spite of the lack of changes in LDLc levels.
Published by Elsevier Ireland Ltd. Open access under CC BY-NC-SA license.1. Introduction
Patients with metabolic syndrome (MetS) experience greater
risk for cardiovascular disease [1] and are characterized by mixed
dyslipidemia, elevated triglycerides (TG) and low high-density li-
poproteins cholesterol (HDL-C), high blood pressure, insulin resis-
tance, central obesity. Recommended optimal values include LDL-
C < 2.59 mmol/L (100 mg/dL), TG < 1.69 mmol/L (150 mg/dL) and
HDL-C > 1.03 mmol/L (40 mg/dL) (male) or >1.29 mmol/L (50 mg/A183, Atlanta VAMC, 1670
7 3222; fax: þ1 404 728 4716.
l.com (N.-A. Le).
ess under CC BY-NC-SA license.dL) (female). Many of MetS patients receive statins to treat dysli-
pidemia, primarily LDL-C, but the optimal values for TG andHDL are
typically not reached.
In addition to elevated fasting plasma triglycerides, MetS pa-
tients are also reported to have elevated postprandial lipemia
which has been linked to the generation of atherogenic remnants of
triglyceride-rich lipoproteins [2e4]. Postprandial hyper-
triglyceridemia has been reported to result in impaired endothelial
function by enhancing oxidative stress [5]. By increasing lipopro-
tein lipase activity via the peroxisomal proliferator activated re-
ceptor alpha (PPARa), ﬁbrate therapy has been linked with
reduction in plasma triglycerides, both in the fasted and fed state
[6,7]. Statin and ﬁbrate combination therapy for MetS patients is
supported by a number of studies [8].
ABT-335 is the choline salt of fenoﬁbric acid and has the advan-
tage of being absorbed rapidly without requiring ﬁrst-pass meta-
bolism as is the case with fenoﬁbrate, the ester form of fenoﬁbric
N.-A. Le et al. / Atherosclerosis 231 (2013) 268e273 269acid [9]. Co-administration of ABT-335 and a number of commonly
used statins has been demonstrated to be safe and efﬁcacious in
reducing LDL-C and TG while increasing HDL-C [10e12].
Oxidative stress may be a new feature of metabolic syndrome
[13]. According to the oxidation hypothesis of atherosclerosis,
native LDL are not taken up and accumulate in macrophages.
However, LDL that have been to be oxidatively modiﬁed could be
avidly taken up by macrophages via scavenger receptors leading to
the formation of foam cells. We have previously reported that
postprandial lipemia is associated with acute increased generation
of oxidatively modiﬁed epitopes on apoB-containing lipoproteins,
especially in patients with documented coronary artery disease and
with inﬂamed endothelium [14,15]. We hypothesize that fasting
and postprandial LDL from high-risk patients may be more sus-
ceptible to oxidative modiﬁcation in vitro [16].
In this randomized, placebo-controlled, double-blind cross-over
studyweexamine the effect of the addition ofABT-335 (135mg/day)
to a stable lipid-lowering regimen on changes in plasma TG, high-
sensitive C reactive protein (hsCRP), and LDL oxidative susceptibil-




The protocol and Informed Consent Form were approved by the
Institutional Review Board of Emory University and the Research and
Development Committee at the Atlanta Veterans Affairs Medical
Center. All participants were recruited from the Lipid/Hypertension
Outpatient Clinic at the Atlanta VAMC.Men andwomen between the
ageof40 and75withany threeof the following clinical characteristics
of metabolic syndrome [17] were eligible for screening, including (i)
TG> 1.69mmol/L, (ii) HDL-C< 1.03 mmol/L (male) or<1.29mmol/L
(female), (iii) high blood pressure (>130/85 mmHg), (iv) abdominal
obesitywithwaist circumference> 102 cm (male) or 88 cm (female),
and (v) elevated fasting blood glucose (6.1e7.0mmol/L). Patientswith
documented type 2 diabetesmellitus under good controlwith diet or
oral agentswere eligible aswell as hypertensive patients under stable
management. Individuals with chronic kidney disease, liver disease
and history of cancer were excluded from participation.
A total of 32 subjects (27 men and 5 women) were randomized
and 2men and 3womenwere lost due to follow-up prior to the ﬁrst
meal challenge study and data from 27 subjects were available for
analysis. Nine participants were African-American (33.3%), 16 par-
ticipantswere Caucasian (59.3%) and the remaining 2were Hispanic.
Themean (SD, range) agewas 62.1 (6.7, 43e72) years. Themean (SD,
range)waist circumference and BMIwere 117.0 (4.7, 95.3e147.3) and
35.1 (4.7, 29.0e44.7), respectively. All 27 participants were under
stable management for high blood pressure and 19 (70.4%) of the
participants were under treatment for type 2 diabetes mellitus. The
mean (SD, range) ofHbA1cwas6.7% (0.78, 5.6e9.0). One subjectwith
aHbA1cof 9% at the screening visit and randomizationhadameanof
8.1% throughout the study period and was included in the ﬁnal
dataset. Among the diabetic subjects, 14 were taking metformin, 2
were controlled with diet only, 2 were receiving pioglitazone and 1
was on insulin. With respect to lipid-lowering therapy, 7 out of 27
(26%)were not on any lipid-lowering agent,1 subjectwas onniaspan
(500 mg/day) at screening, 1 was on pravastatin, 2 were taking
rosuvastatin and the remaining (59%) were taking simvastatin.
2.2. Study protocol
This was a randomized, placebo-controlled, double-blind cross-
over study with two [8-week] treatment periods separated by a[4-week] wash-out period. All participants were scheduled for
follow-up visits every 2 weeks to monitor for safety chemistries,
side-effects and compliance. At the 8th week visit for each
treatment period, all subjects were asked to report to the clinic in
the fasted state without coffee or cigarette smoking for a mini-
mum of 8 h. After collection of fasting blood, participants were
asked to consume a mixed meal that provided 450 kcal within
15 min. The meal challenge used was the McDonald #2 Breakfast
which included English mufﬁn, sausage, egg, hash brown and
orange juice (27 g fat, 41 g carbohydrates and 20 g protein) [18].
Blood samples were collected at 2, 4 and 6 h after the meal for
lipoprotein isolation and composition analysis.
Among the drop-outs, two participants experienced a serious
adverse event that was reported to the Institutional Review Board.
Neither event was classiﬁed as study-related.
2.3. Laboratory analysis
All blood was collected in EDTA and centrifuged within 1 h for
the isolation of plasma. Several aliquots of plasma were prepared
and stored at 80 C within 4 h of collection. In addition, 2 mL of
plasma from each time point were adjusted to a ﬁnal density of
1.21 g/mL using NaBr solution containing 0.2% EDTA and subjected
to ultracentrifugation (39,000 RPM for 48 h at 10 C) using the
Beckman 50.4 Ti rotor for the isolation of the lipoprotein-rich
fraction (1.21Top). The 1.21Top fractions were stored at 80 C
until the participant completed the entire protocol and paired
samples from both treatment periods were then evaluated for
oxidative susceptibility.
Plasma lipids were determined on the Beckman AU480 chem-
istry analyzer using enzymatic methods. Cholesterol and tri-
glycerides were determined using reagents from Beckman
Diagnostics (Fullerton, CA). HDLc and LDLc were determined using
homogeneous reagents from Sekisui Diagnostics (Exton, PA). hsCRP
was determined by immunoturbidometric method using reagents
from Sekisui Diagnostics (Exton, PA).
Lipoprotein particle numbers and sizes were determined by
nuclear magnetic resonance (NMR) spectroscopy (LipoScience, Inc.,
Raleigh, NC) [19] using fasting plasma obtained on two separate
occasions for each treatment period. Plasma was obtained on the
day of the meal challenge and on the follow-up visit immediately
preceding the metabolic study and the mean value was used for
each period.
2.4. Oxidative susceptibility of plasma lipoproteins
Approximately 0.2 mL of 1.21Top fraction was further applied
onto a Superose 6HR 10/30 column connected to an FPLC system
(Pharmacia LKB, Gaithersburg, MD) with multi-port auto-injector
and fraction collector. This size exclusion chromatographic step has
dual function [1]: it allows for the separation of 20 fractions ranging
in size from VLDL to HDL as previously reported [20,21,2] it elimi-
nates potential contamination by NaBr, EDTA and other small mo-
lecular weight proteins, including albumin. This step was
completed within 40 min. Cholesterol and triglyceride proﬁle were
obtained by enzymatic assays and 3 fractions corresponding to LDL
were pooled [15] and used for the oxidation study. Similarly, 3
fractions corresponding to HDL were also combined for the
oxidation study. The continuous formation of conjugated dienes in
the presence of Cuþþ [22] was carried out using the Beckman DU
530 UV/Vis Spectrophotometer equipped with a 6-cell tray. LDL
oxidative susceptibility was assessed under 3 conditions: [1] LDL
auto-oxidation in the absence of Cuþþ as the oxidizing agent [2],
Cuþþ-induced oxidative modiﬁcation of LDL in (45 mg
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Fig. 1. Mean fractional changes in hsCRP and TG during the placebo and ABT-335
periods. For each participant data levels in fasting plasma obtained at each follow-
up visit as well as during the postprandial period are expressed as fraction of base-
line level. Baseline level is deﬁned as the mean value determined at the time of
screening and randomization.
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HDLc þ 12 mmol Cuþþ). The ﬁnal volume in each cell was constant
at 0.75 mL for all samples and the ratio of Cuþþ to cholesterol is
constant in all incubations, 1 mmol of Cuþþ per 5 mg of lipoprotein
cholesterol. Thus, for the LDL þ HDL co-incubation, the ﬁnal con-
centration of Cuþþwas increased by 30% tomatchwith the increase
in total cholesterol contents in the incubation cell. To minimize the
variability between runs, LDL from fasting plasma obtained during
the placebo and the ABT-335 period were assayed together and LDL
from the 4-h postprandial plasma obtained during the placebo and
ABT-335 period were assayed together. Oxidation studies of fasting
and postprandial lipoproteins from the same subject were
completed within 24 h. Longer lag time corresponds to reduced
oxidative susceptibility.
2.5. Statistical analyses
All parameters were checked for normality prior to analysis.
Incremental area under the curve was calculated using the trape-
zoid rule. Paired t-test was used to assess the signiﬁcance of any
changes between placebo and fenoﬁbric acid treatment as well as
difference between fasting and postprandial values. Statistical an-




Table 1 presents the mean lipid parameters after the placebo
and ABT-335 period and the percent changes. For each subject the
values obtained at the last 2 visits of each period were averaged and
used for the analysis. The mean (SD) change in fasting plasma TG
was 20.2% (18.2, p < 0.0002) which was accounted by a 16.1%
(18.9, p < 0.0002) reduction in VLDL particle number as assessed
by NMR spectroscopy with no change in VLDL particle size. There
was a trend for reduction in hsCRP with ABT-335 treatment
(6.1%  39.7, p ¼ 0.06), but it was not statistically signiﬁcant in
this small study. There was no change in any other fasting lipid
parameters.
For the postprandial period, the incremental area under the
curve (iAUC) was calculated for each subject. The iAUC for TG
during the 6-h postprandial period was reduced by 28.5% with ABT-
335 from 224.4 (132.3) to 135.9 (66.2) (p < 0.0005). iAUC for
hsCRP, glucose and insulin was slightly reduced, but the changes
were not statistically signiﬁcant (data not shown).
Fig. 1 illustrates the mean fractional changes in plasma TG and
hsCRP for all subjects throughout the duration of the protocol. The
data are presented with the placebo period being presented as the
ﬁrst phase followed by data from the ABT-335 period.Table 1
Effect of ABT-335 on plasma lipid parameters.
Parameter (SD) Placebo ABT-335 Percent change p-value
TG (mmol/L) 2.7 (1.35) 2.1 (0.90) 20.2 (18.2) p < 0.0002
TC (mmol/L) 4.4 (1.12) 4.3 (1.03) 0.8 (10.8) ns
LDLc (mmol/L) 2.7 (0.83) 2.8 (0.79) 3.8 (15.7) ns
HDLc (mmol/L) 0.91 (0.19) 0.93 (0.19) 3.6 (11.0) ns
VLDLp (mmol/L) 86.6 (46.7) 72.6 (43.4) 16.1 (18.9) p < 0.0002
LDLp (mmol/L) 1274.2 (370.8) 1278.4 (383.0) 0.3 (16.2) ns
HDLp (mmol/L) 29.4 (5.3) 30.0 (5.7) 2.6 (13.6) ns
hsCRP (nmol/L) 60.0 (149.5) 49.5 (49.5) 6.1 (39.7) p < 0.06
iAUC_TG 2.54 (1.49) 1.54 (0.75) 28.5 (42.4) p < 0.0005
iAUC_TG incremental area under the plasma TG curve following the consumption of
a mixed meal.3.2. Oxidative susceptibility
Fig. 2 illustrates the kinetics of conjugated dienes formation for
fasting lipoproteins (Fig. 2A, B, and C) and postprandial lipoproteins
(Fig. 2D, E, and F) for a representative subject. Table 2 summarizes
the results from the oxidative susceptibility study.
With fasting LDL, 56% of the subjects have LDL that undergo
spontaneous oxidation without requiring the addition of Cuþþ as
oxidizing agent, i.e. auto-oxidation. This was the case for both the
placebo and ABT-335 period. In the absence of Cuþþ, there was no
difference in lag time for fasting LDL isolated during the placebo or
ABT-335 period (169.6 versus 171.9 min, Table 2). Postprandial LDL
was slightly more susceptible to auto-oxidation than fasting LDL
during the placebo period, i.e. shorter lag time 151.4 (85.4) min
versus 169.6 (84.3) min (ns). In contrast, with ABT-335 therapy,
postprandial LDL has longer auto-oxidation lag time than fasting
LDL, 212.4 (65.3) versus 171.9 min (88.1) (p < 0.05). During ABT-
335 treatment, postprandial LDL underwent auto-oxidation in
fewer individuals, 37% as compared to 63% during the placebo
period, and among those who underwent auto-oxidation, the lag
time was longer, while on ABT-335 as compared to placebo, sug-
gestive of reduced oxidative susceptibility with ABT-335.
In the presence of Cuþþ, LDL lag time was signiﬁcantly reduced
as compared to the auto-oxidation lag times. Fasting LDL obtained
during ABT-335 treatment had a slightly longer lag time compared
to fasting LDL from the placebo period, but the 16% difference (43.5
versus 37.4 min, ns) was not statistically different. Postprandial
lipemia was associated with a signiﬁcant increased in oxidative
susceptibility of LDL during both the placebo and the ABT-335 pe-
riods as indicated by shorter lag times. During the placebo period,
the mean reduction in postprandial LDL lag time was 21.1% (from
37.4 min for fasting LDL to 29.5 min for postprandial LDL, p < 0.05).
In contrast, during the ABT-335 period, the mean reduction was
more modest, only 12.6% reduction (from 43.5 min for fasting LDL
to 38.0 min for postprandial LDL, ns) (Table 2). During treatment
with ABT-335, postprandial LDL was less susceptible to oxidation
than postprandial LDL from the placebo period, i.e. longer lag times


























































































































































Fig. 2. Kinetics of LDL oxidation for a representative subject during the placebo period (closed symbols) and ABT-335 period (open symbols). (A) fasting LDL in the absence of Cuþþ;
(B) fasting LDL in the presence of Cuþþ; (C) co-incubation of fasting LDL and autologous fasting HDL in the presence of Cuþþ; (D) postprandial LDL in the absence of Cuþþ, (E)
postprandial LDL in the presence of Cuþþ, and (F) co-incubation of postprandial LDL and autologous postprandial HDL in the presence of Cuþþ.
Table 2
Effect of ABT-335 therapy on LDL oxidative susceptibility.
Lag time, min
Mean (SD)
Placebo ABT-335 1 2 3
L0 169.6 (84.3) 171.9 (88.1) ns
L4 151.4 (85.4) 212.4 (65.3) p < 0.007 ns p < 0.05
L0 þ Cuþþ 37.4 (17.6) 43.5 (21.1) ns
L4 þ Cuþþ 29.5 (16.3) 38.0 (13.9) p < 0.015 p < 0.05 ns
L0 þ H0 þ Cuþþ 19.3 (10.1) 25.9 (13.6) p < 0.03
L4 þ H4 þ Cuþþ 16.4 (8.1) 20.1 (10.7) p < 0.09 ns ns
L0 and H0 indicate LDL and HDL isolated from fasting plasma; L4 and H4 indicate
LDL and HDL isolated from postprandial plasma (4 h after meal consumption).
(1) Signiﬁcance for comparison between Placebo and ABT-335; (2) Signiﬁcance for
comparison between fasting and postprandial LDL (L0 and L4) during the placebo
period; and (3) Signiﬁcance for comparison between fasting and postprandial LDL
(L0 and L4) during ABT-335 treatment.
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Cuþþ-induced oxidative modiﬁcation and actually increased
oxidative susceptibility of LDL as demonstrated by shorter lag time
as compared to LDL incubated in the absence of autologous HDL,
independent of treatment phase. Lag time for fasting LDL was
increased by 48.2% (19.3 versus 37.4, p< 1E-06) during placebo and
by 40.6% (25.9 versus 43.5, p < 0.002) during ABT-335. LDL lag time
in the presence of matching HDL during ABT therapy was longer
(34.2%) as compared to LDL in the presence of HDL from the placebo
phase (25.9 versus 19.3min, p< 0.03), indicative of some protective
effect of ABT-335 treatment. In the presence of postprandial HDL,
postprandial LDL also had longer lag time (22.6%) during the ABT-
335 phase as compared to the placebo phase, but the difference
did not reach statistical signiﬁcance.
N.-A. Le et al. / Atherosclerosis 231 (2013) 268e2732724. Discussion
While reduction in plasma levels of atherogenic LDL remains the
primary target for therapeutic intervention, there is increasing
evidence that plasma triglycerides [23] and postprandial lipemia
[3,24] may contribute independently to the increased risk of car-
diovascular disease. This may be of special importance in patients
with mixed dyslipidemia. Fenoﬁbric acid (ABT-335) has been re-
ported to be safe and efﬁcacious in concomitantly reducing plasma
cholesterol and plasma triglycerides when co-administered with a
variety of statins [10e12]. In addition to reduction in fasting TG,
ﬁbrate derivatives have also been reported to reduce postprandial
lipemia [6,7,25e27]. Another interest in the ﬁbrate class of agents is
on the increase in HDLc that has been linked to reduction in CVD
risk [28]. In addition to its role in reverse cholesterol transport [29],
HDL has been shown to have anti-inﬂammatory properties [30].
HDL has also been reported to protect LDL from oxidative modiﬁ-
cation and to protect cells against apoptosis induced by oxidized
LDL [31]. These properties of HDL have been reported to be tran-
siently affected by a number of physiologic challenges [32,33] such
as infection, meal consumption and physical activity.
As previously shown by others, signiﬁcant reduction in fasting
and postprandial TG was observed for fenoﬁbric acid [9]. While
HDLc increased, ranging from 3 to 30%, in half of the participants
(48.1%), the overall change, did not reach statistical signiﬁcant in
this small group of subjects, however. Similarly, there was a trend
toward lower fasting and postprandial hsCRP (as assessed by iAUC)
with ABT-335, but the variability in hsCRP in this group was high
and the difference was not statistically signiﬁcant.
This report focused on oxidative susceptibility of LDL isolated
from fasting and from postprandial plasma and the ability of
autologous HDL to modulate LDL oxidation in patients with meta-
bolic syndrome who are receiving either placebo or fenoﬁbric acid
in addition to current lipid-lowering regimen. Participants were
recruited from a typical specialty clinic that follows patients with
multiple metabolic disorders who require close management for
cholesterol, blood pressure, and glycemia. Metabolic studies were
performed while the participants were on stable medications with
the addition of either placebo or fenoﬁbric acid.
Pilot unpublished data from a cross-sectional study in subjects
with various clinical conditions, freshly isolated LDL high-risk in-
dividuals were more likely to undergo spontaneous auto-oxidation
in the absence of any oxidizing catalyst. Indeed in this study of
patients with metabolic syndrome, 56% of the participants had
fasting LDL that underwent auto-oxidation during both placebo
and ABT-335 periods. In spite of signiﬁcant reductions in plasma TG
with fenoﬁbric acid, there was no difference in LDL auto-oxidation
between the two periods. This may be due to the fact that fasting
LDL reﬂects the balance of pro-oxidant/anti-oxidant environment
from previous days and meals.
By contrast, our study demonstrated that postprandial LDL
which would reﬂect the status of the immediate environment
exhibited oxidative properties that were more sensitive to drug
therapy. During the placebo period, following the oxidative stress
associated with meal consumption, 63% subjects had postprandial
LDL that were susceptible to auto-oxidationwithout requiring Cuþþ
as the oxidizing agent. During the ABT-335 period, fewer subjects
(37%) had postprandial LDL that underwent auto-oxidation. This
suggests that ABT-335 therapy may be associated with reduction in
the oxidative state of postprandial LDL.
In one earlier report, treatment of patients with primary
hypertriglyceridemia with micronized fenoﬁbrate (200 mg/day)
reduced the oxidative susceptibility of LDL to Cuþþ-induced
oxidation as evidenced by an increase in lag time by 32% [34]. This
is conﬁrmed in our study. With fenoﬁbric acid treatment, bothfasting and postprandial LDL had longer lag time compared to the
corresponding LDL lag time from the placebo period (43.5 versus
37.4 min for fasting LDL and 38.0 versus 29.5 min for postprandial
LDL). Statistical signiﬁcance was reached, however, only for post-
prandial LDL (Table 2). It is possible that the variability in oxidative
status prior to the collection of the fasting plasmamay contribute to
the lack of statistical signiﬁcance in this small group of subjects.
Under normal conditions co-incubation with HDL is expected to
quench the activity of Cuþþ, resulting in a prolonged lag time for
LDL. In this group of patients with metabolic syndrome under
aggressive management for blood pressure, glucose and choles-
terol, co-incubation with autologous HDL failed to increase LDL lag
time (37.4 in the absence of HDL as compared to 19.3 min in the
presence of HDL during the placebo phase and 43.5 versus
25.9 min) during the ABT-335 phase. The percent change in LDL lag
time with HDL during the placebo and ABT-335 phase were not
different, 48 versus 40%with fasting lipoproteins and 44 versus 47%
during postprandial lipemiawould suggest that while ABT-335may
have an overall impact on LDL oxidative susceptibility in the fasted
as well as postprandial state, HDL anti-oxidant function was not
fully restored. Improvement in HDL function could be observed in
some subjects, but there was no change overall. It is possible that
the lack of a signiﬁcant increase in HDLc levels in this study may
explain the lack of anti-oxidant protection.
Several features of the incubation conditions could affect our
results. Presence of albumin and EDTA in the incubation mixtures
could affect the oxidative susceptibility of the lipoproteins. By
adding a size exclusion chromatographic step to the isolation of
plasma lipoproteins by density we have minimized these sources of
antioxidant contaminants. In fact, HDL fractions which are isolated
at a higher density would be more likely to include albumin and
should be more protective. In all cases, addition of HDL, isolated by
density ultracentrifugation and column chromatography, resulted
in increased oxidative susceptibility, suggestive of absence of al-
bumin as an antioxidant. The actual concentration of Cuþþ in the
incubations containing both LDL and HDL is higher than in in-
cubations with LDL alone. The increase in Cuþþ concentration was
necessary to match with the increase in lipid contents in the
mixture. In preliminary studies, failure to keep the ratio of Cuþþ to
cholesterol in the mixture constant will affect lag time for the li-
poproteins. Alternately, we could increase the ﬁnal volume of the
incubationmixture. Another potential confounder in this analysis is
the decision to examine the function of autologous HDL at a ﬁxed
ratio of 3:1 for LDLc:HDLc. Varying the ratio of LDLc:HDLc in the
incubation to match the ratio present in plasma may provide a
better estimate of the net effect of HDL, however, data from our
laboratory in other subjects would suggest that the direction of the
changewould not be affected as has been observed in other studies.
Furthermore, with the lower HDLc levels in this group of subjects,
the ratio of LDLc:HDLc in this study was actually higher than 3:1.
We would have expected that with a higher concentration of HDLc
to LDLc in the in vitro condition, there should have greater anti-
oxidant protection if HDL is functional.
Apparent weaknesses in this report include the small number of
subjects as well the heterogeneity in the medication regimen
currently being received by the participants. The primary objective
in this study is the effect of adding fenoﬁbric acid to current stable
lipid and glucose medications to the oxidative properties of plasma
lipoproteins isolated in the fasted and postprandial state. Since each
participant served as his/her own control with the only difference
being the addition of either a placebo or a ﬁxed dose of fenoﬁbric
acid, the ﬁndings should not affected by neither the small sample
size nor the heterogeneity of the subjects. In fact, we would expect
the effect on oxidative susceptibility may even be stronger if all of
the subjects had comparable high-risk metabolic abnormalities.
N.-A. Le et al. / Atherosclerosis 231 (2013) 268e273 273In conclusion, fenoﬁbric acid (ABT-335 at 135 mg/day), admin-
istered in addition to current medications, is efﬁcacious in reducing
fasting and postprandial hypertriglyceridemia in MetS patients. In
addition, the current data suggest that the oxidative susceptibility
of fasting and postprandial LDLmay be reduced with fenoﬁbric acid
therapy, in spite of no change in LDLc levels. With minimal changes
in HDLc, HDL remains dysfunctional with respect to its antioxidant
properties.
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